Corrigendum to “Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay” [Toxicology in Vitro (2017) 60–71](S0887233317301261)(10.1016/j.tiv.2017.05.010);Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay

Toxicology in Vitro

Volumn 45, Issue , 2017, Pages 60-71

  Zwartsen, Anne ^a,b   Verboven, Anouk H A ^b   van Kleef, Regina G D M ^b   Wijnolts, Fiona M J ^b   Westerink, Remco H S ^b   Hondebrink, Laura ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Designer drugs; Dopamine transporter; Drug screening; Fluorescent monoamine substrate; Norepinephrine transporter; Serotonin transporter

Indexed keywords

1 PHENYL 2 (1 PYRROLIDINYL) 1 PENTANONE; 2,5 DIMETHOXY 4 BROMOPHENETHYLAMINE; 4 BROMO 2,5 DIMETHOXY N (2 METHOXYBENZYL)PHENETHYLAMINE; 4 FLUOROAMPHETAMINE; 4 IODO 2,5 DIMETHOXY N (2 METHOXYBENZYL)PHENETHYLAMINE; 4 METHOXYMETHAMPHETAMINE; 5 (2 AMINOPROPYL)BENZOFURAN; AMPHETAMINE; COCAINE; DOPAMINE TRANSPORTER; FLUOXETINE; METHOXETAMINE; MIDOMAFETAMINE; NORADRENALIN TRANSPORTER; PHENETHYLAMINE; PSYCHOTROPIC AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; AMPHETAMINE DERIVATIVE; NEUROTRANSMITTER TRANSPORTER;

ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; INTERMETHOD COMPARISON; MICROPLATE READER; NONHUMAN; RADIOMETRY; TOXICITY TESTING; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HEK293 CELL LINE;

AMPHETAMINES; COCAINE; HEK293 CELLS; HUMANS; MOLECULAR STRUCTURE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTRANSMITTER TRANSPORT PROTEINS; PSYCHOTROPIC DRUGS;

EID: 85019609912     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2019.104631     Document Type: Erratum

References (106)

1. Adamowicz, P., Zuba, D., Byrska, B., Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB). Forensic Sci. Int. 24 (2014), 126–132, 10.1016/j.forsciint.2014.10.016.
2. Adamowicz, P., Gieron, J., Lechowicz, W., Skulska, A., Tokarczyk, B., The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland. Drug Test. Anal. 8:1 (2016), 63–70.
3. Al-Abri, S., Meier, K.H., Colby, J.M., Smollin, C.G., Benowitz, N.L., Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels. Clin. Toxicol. 52 (2014), 1292–1295.
4. Angrist, B., Corwin, J., Bartlik, B., Cooper, T., Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol. Psychiatry 722 (1987), 1357–1368, 10.1016/0006-3223(87)90070-9.
5. Baumann, M.H., Partilla, J.S., Lehner, K.R., Thorndike, E.B., Hoffman, A.F., Holy, M., Rothman, R.B., Goldberg, S.R., Lupica, C.R., Sitte, H.H., Brandt, S.D., Tella, S.R., Cozzi, N.V., Schindler, C.W., Powerful cocaine-like actions of 3,4-Methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive “bath salts” products. Neuropsychopharmacology 38 (2013), 552–562, 10.1038/npp.2012.204.
6. Bernstein, A.I., Stout, K.A., Miller, G.W., A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport. J. Neurosci. Methods 15 (2012), 357–366, 10.1016/j.jneumeth.2012.06.002.
7. Brajkovic, G., Babic, G., Stosic, J.J., Tomasevic, G., Rancie, D., Kilibarda, V., Fatal cocaine intoxication in a body packer. Vojnosanit. Pregl. 73 (2016), 198–201, 10.2298/VSP141105022B.
8. Butterfield, M., Riguzzi, C., Frenkel, O., Nagdev, A., Stimulant-related Takotsubo cardiomyopathy. Am. J. Emerg. Med., 33, 2015 476.e1–476.e3.
9. Bystrowska, B., Adamczyk, P., Moniczewski, A., Zienwska, M., Fuxe, K., Filip, M., LC/MS/MS evaluation of cocaine and its metabolites in different brain areas, peripheral organs and plasms in cocaine self-administered rats. Pharmacol. Rep. 64 (2012), 1337–1349, 10.1016/S1734-1140(12)70931-3.
10. Cone, E.J., Pharmacokinetics and pharmacodynamics of cocaine. J. Anal. Toxicol. 19 (1995), 459–478, 10.1093/jat/19.6.459.
11. Cozzi, N.V., Sievert, M.K., Shulgin, A.T., Jacobill, P., Rhuolo, A.E., Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur. J. Pharmacol. 381 (1999), 63–69, 10.1016/S0014-2999(99)00538-5.
12. Duineveld, C., Vroegop, M., Schouren, L., Hoedemaekers, A., Schouten, J., Moret-Hartman, M., Kramers, C., Acute intoxications: differences in management between six Dutch hospitals. Clin. Toxicol. 50 (2012), 120–128.
13. Eiden, C., Mathieu, O., Catala, P., Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin. Toxicol. (Phila.) 51 (2013), 899–903, 10.3109/15563650.2013.847187.
14. Elfving, B., Bjørnholm, B., Ebert, B., Knudsen, B.M., Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies. Synapse 41 (2001), 203–211.
15. Elliot, S., Evans, J., A 3-year review of new psychoactive substances in casework. Forensic Sci. Int. 243 (2014), 55–60, 10.1016/j.forsciint.2014.04.017.
16. EMCDDA, New psychoactive substances in Europe: an update from the EU early warning system. http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances, 2015 (accessed on 6.6.2016).
17. EMCDDA, European drug report 2015: trends and developments. http://www.emcdda.europa.eu/publications/edr/trends-developments/2015, 2015 (accessed on 5.6.2016).
18. Eshleman, A.J., Wolfrum, K.M., Hatfield, M.G., Johnson, R.A., Murphy, K.V., Janowsky, A., Substituted methcathinones differ in transporter and receptor interactions. Biochem. Pharmacol. 85 (2013), 1803–1815, 10.1016/j.bcp.2013.04.004.
19. Flash Eurobarometer 401, Young people and drugs. Report. Conducted by TNS Political & Social at the request of the European Commission, Directorate-General for Justice. http://www.drugsandalcohol.ie/22196/13/Eurobarometer%20401%20Young%20people%20and%20drugs%20-%20full%20report.pdf, 2014 (accessed 6.5.2016).
20. Fleckenstein, A.E., Volz, T.J., Riddle, E.L., Gibb, J.W., Hanson, G.R., New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 681–698, 10.1146/annurev.pharmtox.47.120505.105140.
21. Fowler, A., Seifert, N., Acker, V., Woehrle, T., Kilpert, C., de Saizieu, A., A nonradioactive high-throughput/high-content assay for measurement of the human serotonin reuptake transporter function in vitro. J. Biomol. Screen. 2006 (2006), 1027–1034.
22. Greene, S.L., Kerr, F., Braitberg, G., Review article: amphetamines and related drugs of abuse. Emerg. Med. Australas. 20 (2008), 391–402, 10.1111/j.1742-6723.2008.01114.x.
23. Hasegawa, K., Suzuki, P., Wurita, A., Minakata, K., Yamagishi, I., Nozawa, H., Gonmori, K., Watanabe, K., Postmortem distribution of α-pyrrolidinovalerophenone and its metabolite in body fluids and solid tissues in a fatal poisoning case measured by LC-MS-MS with the standard addition method. Forensic Toxicol. 32 (2014), 225–234, 10.1007/s11419-014-0227-8.
24. Haunsø, A., Buchanan, D., Pharmalogical characterization of a fluorescent uptake assay for the noradrenaline transporter. J. Biomol. Screen. 12 (2007), 378–384, 10.1177/1087057107299524.
25. Hendrickson, H., Laurenzana, E., Owens, S.M., Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J. 8 (2006), E709–E717, 10.1208/aapsj080480.
26. Henry, M.E., Schmidt, M.E., Hennen, J., Villafuerte, R.A., Butman, M.E., Tran, P., Kerner, L.T., Cohen, B., Renshaw, P.F., A comparison of brain and serum pharmacokinetics of r-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology 30 (2005), 1576–1583.
27. Ho, R.Y., Gerona, R., Olson, K.R., Clinical course of 4-bromo-2,5-dimethoxyphenylamine (2C-B) intoxication with laboratory confirmation. Clin. Toxicol. (Phila.) 51 (2013), 666–667.
28. Hohmann, N., Mikus, G., Czock, D., Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch. Arztebl. Int. 111 (2014), 139–147.
29. Holladay, J.W., Michael, J.D., Yoo, S.D., Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels. J. Pharmacol. Exp. Ther. 26 (1998), 20–24.
30. Holmgren, A., Holmgren, P., Kugelberg, F.C., Jones, A.W., Ahlner, J., High re-arrest rates among drug-impaired drivers despite zero-tolerance legislation. Accid. Anal. Prev. 40 (2008), 534–540, 10.1016/j.aap.2007.08.009.
31. Hondebrink, L., Meulenbelt, J., van Kleef, R.G.D.M., van den Berg, M., Westerink, R.H.S., Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse. Neurotoxicology 32 (2011), 823–827.
32. Hondebrink, L., Meulenbelt, J., Meijer, M., van den Berg, M., Westerink, R.H.S., High concentrations of MDMA (‘ecstasy’) and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells. Neuropharmacology 61 (2011), 202–208.
33. Hondebrink, L., Meulenbelt, J., Rietjens, S.J., Meijer, M., Westerink, R.H.S., Methamphetamine, amphetamine, MDMA (‘ecstasy’), MDA and mCPP modulate electrical and cholinergic input in PC12 cells. Neurotoxicology 33 (2012), 255–260.
34. A receptors by mixtures of commonly used drugs of abuse. Neurotoxicology 35 (2013), 23–29.
35. Hondebrink, L., Nugteren-van Lonkhuyzen, J.J., Van den Gouwe, D., Brunt, T.M., Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend. 147 (2015), 109–115, 10.1016/j.neuro.2016.04.020.
36. A receptor by piperazine derivatives: a novel mode of action. Neurotoxicology 51 (2015), 1–9.
37. Hondebrink, L., Verboven, A.H.A., Drega, W.S., Schmeink, S., de Groot, M.W.G.D.M., van Kleef, R.G.D.M., Wijnolts, F.M., de Groot, A., Meulenbelt, J., Westerink, R.H., Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings. Neurotoxicology 55 (2016), 1–9, 10.1016/j.neuro.2016.04.020.
38. Horsley, R.R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., Palenicek, T., Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue — behavioural, pharmcokinetic and metabolic studies in the Wistar rat. Brain Res. Bull. 126 (2016), 102–110, 10.1016/j.brainresbull.2016.05.002.
39. Howell, L.L., Kimmel, H.L., Monoamine transporters and psychostimulant addiction. Biochem. Pharmacol. 75 (2008), 196–217, 10.1016/j.bcp.2007.08.003.
40. Huang, H.L., Hsing, H.W., Lai, T.C., Chen, Y.W., Lee, R.T., Chan, H.T., Lyu, P.C., Lin, S.T., Lin, C.W., Lai, C.H., Chang, H.T., Chou, H.C., Chan, H.L., Trypsin-induced proteome alteration during cell subculture in mammalian cells. J. Biomed. Sci., 17, 2010, 36, 10.1186/1423-0127-17-36.
41. Hyttel, J., Citalopram – pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 6 (1982), 227–295.
42. Isenschmid, D.S., Fishman, M.W., Foltin, R.W., Caplan, Y.H., Concentration of cocaine and metabolites in plasma of humans following intravenous administration and smoking of cocaine. J. Anal. Toxicol. 16 (1992), 311–314, 10.1093/jat/16.5.311.
43. Javaid, J.I., Fischman, M.W., Schuster, C.R., Dekirmenjian, H., Davis, J.M., Cocaine plasma concentration: relation to physiological and subjective effects in humans. Science 202 (1978), 227–228, 10.1126/science.694530.
44. Jeffcoat, A.R., Perez-Reyes, M., Hill, J.M., Sadler, B.M., Cook, C.E., Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. Drug Metab. Dispos. 17 (1989), 153–159.
45. Jenkins, A.J., Keenan, R.M., Henningfield, J.E., Cone, E., Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J. Anal. Toxicol. 26 (2002), 82–392, 10.1093/jat/26.7.382.
46. Johansen, S.S., Hansen, T.M., Isomers of fluoroamphetamines detected in forensic cases in Denmark. Int. J. Legal Med. 126 (2012), 541–547, 10.1007/s00414-012-0671-0.
47. Jørgensen, S., Nielsen, E.O., Peters, D., Dyhring, T., Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity. J. Neurosci. Methods 169 (2008), 168–176, 10.1016/j.jneumeth.2007.12.004.
48. +, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter. ACS Chem. Neurosci. 15 (2013), 856–869, 10.1021/cn400038u.
49. Karson, C.N., Newton, J.E.O., Livingston, R., Jolly, J.B., Cooper, J.B., Sprigg, J., Komoroski, R.A., Human brain fluoxetine concentrations. J. Neuropsychiatr. Clin. Neurosci. 5 (1993), 322–329, 10.1176/jnp.5.3.322.
50. Kimmel, H.L., Carroll, F.I., Kuhar, M.J., Locomotor stimulant effects of novel phenyltropanes in the mouse. Drug Alcohol Depend. 65 (2001), 25–36, 10.1016/S0376-8716(01)00144-2.
51. 19F spin relaxation and localized spectroscopy of fluoxetine in the brain. Magn. Reson. Med. 31 (1994), 204–211.
52. Koob, G.F., Volkow, N.D., Neurocircuitry of addiction. Neuropsychopharmacology 35 (2010), 217–238, 10.1038/npp.2009.110.
53. Korpi, E.R., Hollander den, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, R.D., Hyytiä, P., Dawe, G.S., Mechanisms of action and persistent neuroplasticity by drugs of abuse. Pharmacol. Rev. 46 (2015), 872–1004, 10.1124/pr.115.010967.
54. Kyriakou, C., Marinelli, E., Frati, P., Santurro, A., Afxentiou, M., Zaami, S., Busardo, F.P., NBOMe: new potent hallucinogens-pharmacology, analytical methods, toxicities, fatalities: a review. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 3270–3281.
55. Laskowski, L., Elbakoush, F., Calvo, J., Exantus-Bernard, G., Fong, J., Polkis, J.L., Polkis, A., Nelson, L.S., Evolution of the NBOMes: 25c- and 25B- sold as 25I-NBOMe. J. Med. Toxicol. 11 (2015), 237–241, 10.1007/s13181-014-0445-9.
56. Lee, M., Song, Y., Hwang, B., Chau, C., Determination of amphetamine and methamphetamine in serum via headspace derivatization solid-phase microextraction-gas chromatography-mass spectrometry. J. Chromatogr. A 896 (2000), 265–273, 10.1016/s0021-9673(00)00596-3.
57. Madias, J., Takotsubo syndrome due to 4-fluoroamphetamine. Clin. Toxicol. (Phila.), 53, 2015, 136.
58. Marona-Lewicka, D., Rhee, G.S., Sprague, J.E., Nichols, D.E., Psychostimulant-like effects of p-fluoramphetamine in the rat. Eur. J. Pharmacol. 287 (1995), 105–113, 10.1016/0014-2999(95)00478-5.
59. Martel, F., Keating, E., Uptake of 1-methyl-4-phenylpyridinium (MPP +) by the JAR human placental choriocarcinoma cell line: comparison with 5-hydroxytryptamine. Placenta 24 (2003), 361–369, 10.1053/plac.2002.0917.
60. Marusich, J.A., Antonazzo, K.R., Wiley, J.L., Blough, B.E., Partilla, J.S., Baumann, M.H., Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87 (2014), 206–213, 10.1016/j.neuropharm.2014.02.016.
61. Meltzer, P.C., Butler, D., Deschamps, J.R., Maddras, B.K., 1-(4-Methylphenyl)-2-pyrrolidin-1-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 49 (2006), 1420–1432, 10.1021/jm050797a.
62. Miliano, C., Serpelloni, G., Rimondo, C., Merue, M., Marti, M., De Luca, M.A., Neuropharmacology of New Psychoactive Substanes (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front. Neurosci., 10, 2016.
63. Mlinar, B., Corradetti, R., Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur. J. Neurosci. 18 (2003), 1559–1571.
64. Mueller, M., Yuan, J., Felim, A., Neudorffer, A., Peters, F.T., Maurer, H.H., McCann, U.D., Largeron, M., Ricaurte, G.A., Further studies on the role of metabolites in (+/)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab. Dispos. 3 (2009), 2079–2086, 10.1124/dmd.109.028340.
65. Mugele, J., Nañagas, K.A., Tormoehlen, L.M., Serotonin syndrome associated with MDPV use: a case report. Ann. Emerg. Med. 60 (2012), 100–102, 10.1016/j.annemergmed.2011.11.033.
66. Nagai, F., Nonaka, R., Satoh, H., Kamimura, K., The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 559 (2007), 132–137, 10.1016/j.ejphar.2006.11.075.
67. Orsulak, P.J., Kenney, J.T., Debus, J.R., Crowley, G., Wittman, P.D., Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC, with ultraviolet detection. Clin. Chem. 345 (1988), 1875–1878.
68. +. J. Neurochem. 114 (2010), 1019–1029, 10.1111/j.1471-4159.2010.06828.x.
69. Pálenícek, T., Malíková, M., Rohanová, M., Novák, T., Horácek, J., Fujáková, M., Höschl, C., Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats. Pharmacol. Biochem. Behav. 98 (2011), 130–139, 10.1016/j.pbb.2010.12.011.
70. Polkis, J.L., Charles, J., Wolf, C.E., Poklis, A., High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomed. Chromatogr. 27 (2013), 1794–1800, 10.1002/bmc.2999.
71. Polkis, J.L., Nanco, C.R., Troendle, M.M., Wolf, C.E., Polkis, A., Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test. Anal. 6 (2014), 764–769, 10.1002/dta.1522.
72. Polkis, J.L., Devers, K.G., Arbefeville, E.F., Pearson, J.M., Houston, E., Polkis, A., Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci. Int. 234 (2014), e14–e20, 10.1016/j.forsciint.2013.10.015.
73. Rambourg Schepens, M.O., Fluoxetine (PIM 651). International programme on chemical safety poisons information monograph 651. http://www.inchem.org/documents/pims/pharm/pim651.htm, 1996 (accessed 13.7.2016).
74. Renshaw, P.F., Guimaraes, A.R., Fava, M., Rosenbaum, J.F., Pearlman, J.D., Flood, J.G., Puopolo, P.R., Clancy, K., Gonzalez, R.G., Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am. J. Psychiatry 149 (1992), 1592–1594.
75. Rickli, A., Hoener, M.C., Liechti, M.E., Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol. 25 (2015), 365–376, 10.1016/j.euroneuro.2014.12.012.
76. Rickli, A., Liethi, D., Reinisc, J., Buchy, D., Hoener, M.C., Liechti, M.E., Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives aof 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99 (2015), 546–553, 10.1016/j.neuropharm.2015.08.034.
77. Rickli, A., Kopf, S., Hoener, M.C., Liechti, M.E., Pharmacological profile of novel psychoactive benzofurans. Br. J. Pharmacol. 172 (2015), 3412–3425, 10.1111/bph.13128.
78. Rietjens, S.J., Hondebrink, L., Westerink, R.H.S., Meulenbelt, J., Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions. Crit. Rev. Toxicol. 42 (2012), 854–876, 10.3109/10408444.2012.725029.
79. Rivière, G.J., Gentry, W.B., Owens, S.M., Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J. Pharmacol. Exp. Ther. 292 (2000), 1042–1047, 10.1371/journal.pone.0052060.
80. Rohanová, M., Pálenícek, T., Balíková, M., Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. Toxicol. Lett. 178 (2008), 29–36, 10.1016/j.toxlet.2008.01.017.
81. Röhrich, J., Becker, J., Kaufmann, T., Zorntlein, S., Urban, R., Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. Forensic Sci. Int. 215 (2012), 3–7, 10.1016/j.forsciint.2011.04.004.
82. Rosenauer, R., Luf, A., Holy, M., Freissmuth, M., Schmid, R., Sitte, H.H., A combined approach using transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of unknown content. ACS Chem. Neurosci. 4 (2013), 182–190, 10.1021/cn3001763.
83. Rudnick, G., Wall, S.C., The molecular mechanism of “ecstasy” [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 1812–1817.
84. Saldaña, S.N., Barker, E.L., Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neurosci. Lett. 354 (2004), 209–212.
85. Schwartz, J.W., Blakely, R.D., DeFelice, L.J., Binding and transport in norepinephrine transporters: real-time, spatially resolved analysis in single cells using a fluorescent substrate. J. Biol. Chem. 278 (2003), 9768–9777, 10.1074/jbc.M209824200.
86. Scottish Government Social Research, New psychoactive substances – evidence review. Scottish Government Publications Website: http://www.gov.scot/Resource/0045/00457682.pdf, 2014 (Accessed on 13-03-2017).
87. Shields, J.E., Dargan, P.I., Wood, D.M., Puchnarewicz, M., Davies, S., Waring, W.S., Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin. Toxicol. (Phila.) 50 (2012), 438–440, 10.3109/15563650.2012.683437.
88. Shiue, C.Y., Shiue, G.G., Rysavy, J.A., Pleus, R.C., Huang, H., Bai, L.Q., Cornish, K.G., Sunderland, J.J., Frick, M.P., Fluorine-18 and carbon-11 labeled amphetamine analogs-synthesis, distribution, binding characteristics in mice and rats and a PET study in monkey. Nucl. Med. Biol. 20:8 (1993), 973–981.
89. Simmler, L.D., Liechti, M.E., Interactions of cathinone NPS with human transporters and receptors in transfected cells. Curr. Top. Behav. Neurosci. 2016 (2016), 1–24, 10.1007/7854_2016_20.
90. Simmler, L.D., Buser, T., Donzelli, M., Schramm, Y., Dieu, L.H., Huwyler, J., Chaboz, S., Hoener, M.C., Liechti, M.E., Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 168 (2013), 458–470, 10.1111/j.1476-5381.2012.02145.x.
91. Simmler, L.D., Rickli, A., Schramm, Y., Hoener, M.C., Liechti, M.E., Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem. Pharmacol. 88 (2014), 237–244, 10.1016/j.bcp.2014.01.024.
92. Strauss, W.L., Dager, S.R., Magnetization transfer of fluoxetine in the human brain using fluorine magnetic resonance spectrometry. Biol. Psychiatry 49 (2001), 798–802.
93. Strauss, W.L., Unis, A.S., Cowan, C., Dawson, G., Dager, S.R., Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am. J. Psychiatry 159 (2002), 755–7620.
94. Sykutera, M., Cychowska, M., Bloch-Buguslawska, E., A fatal case of pentedrone and α-pyrrolidinovalerophenone poisoning. J. Anal. Toxicol. 39 (2015), 324–329, 10.1093/jat/bkv011.
95. de la Torre, R., Farré, M., Ortuño, J., Mas, M., Brenneisen, R., Roset, P.N., Segura, J., Cami, J., Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 49 (2000), 104–109, 10.1046/j.1365-2125.2000.00121.x.
96. Torres, G.E., Gainetdinov, R.R., Caron, M.G., Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 4 (2003), 13–25, 10.1038/nrn1008.
97. Tsuruda, P.R., Yung, J., Martin, W.J., Chang, R., Mai, N., Smith, J.A.M., Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters. J. Pharmacol. Toxicol. Methods 61 (2010), 192–204, 10.1016/j.vascn.2009.12.003.
98. UNODC, World drug report. United Nations Office on Drugs and Crime, 2016, Nations publication, United https://www.unodc.org/wdr2016/en/index.html?lf=1&lng=en (accessed on 5.6.2016).
99. Verrico, C.D., Miller, G.M., Madras, B.K., MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189 (2007), 489–503, 10.107/s00213-005-0174-5.
100. Vevelstad, M., Oiestad, E.L., Middelkoop, G., Hasvold, I., Lilleng, P., Delaveris, G.J.M., Eggen, T., Mørland, J., Arnestad, M., The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications. Forensic Sci. Int. 219 (2012), 151–157, 10.1016/j.forsciint.2011.12.014.
101. Volkow, N.D., Fowler, J.S., Wang, G.J., Baler, R., Telang, F., Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (2009), 3–8, 10.1016/j.neuropharm.2008.05.022.
102. White, S.J., Hendrickson, H.P., Atchley, W.T., Laurenzana, E.M., Gentry, W.B., Williams, D.K., Owens, S.M., Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metab. Dispos. 42 (2014), 1285–1291, 10.1124/dmd.114.056879.
103. Wijers, C.H.W., van Litsburg, R.T.H., Hondebrink, L., Niesink, R.J.M., Croes, E.A., Acute toxic effects related to 4-fluoroamphetamine. Lancet, 389, 2017, 600.
104. Wood, D.M., Davies, S., Puchnarewicz, M., Johnston, A., Dargan, P.I., Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 68 (2012), 853–856, 10.1007/s00228-011-1199-9.
105. Wright, T.H., Harris, C., Twenty-one cases involving alpha-pyrrolidinovalerophenone (α-PVP). J. Anal. Toxicol. 40 (2016), 396–402, 10.1093/jat/bkw029.
106. Yoon, Y.S., Cho, T., Yoon, S.H., Min, C.K., Lee, C., N-methyl amine-substituted fluoxetine derivatives: new dopamine transporter inhibitors. Arch. Pharm. Res. 32 (2009), 1663–1671, 10.1007/s12272-009-2201-2.